The mRNA flu shot, mFlusiva, is currently available in limited quantities across more than 13,000 locations in the United States. Approval for its use was granted in August for adults aged 50 and older, following a phased launch strategy by Moderna. Traditional flu vaccine options include standard-dose vaccines made by growing the influenza virus in eggs (Fluzone, Fluarix, FluLaval, and Afluria), as well as egg-free enhanced vaccines like Flublok and Flucelvax.
The Centers for Disease Control and Prevention (CDC) has indicated that all flu shots are now trivalent, due to the cessation of the B/Yamagata lineage after March 2020. While a phase III study demonstrated greater immunogenicity of mFlusiva compared to Fluzone High-Dose in adults 65 and older, head-to-head clinical outcome studies are lacking. The mRNA vaccine exhibits greater reactogenicity, including higher rates of injection-site pain, fatigue, headache, and myalgia, which may be a consideration for some individuals. The FDA initially raised concerns about the comparator used in Moderna’s application for the vaccine, but later approved it with accelerated approval for those 65 and older, pending a postmarketing effectiveness study. The adaptability of the mRNA platform offers potential for future vaccine development, but policy adjustments may be needed to shorten the strain selection timeline.”}